Reports find Raindrop hydrogel corneal inlay can help presbyopes

Article

According to several presentations given during the American Society of Cataracts and Refractive Surgery 2014 meeting, the investigational Raindrop (ReVision Optics) transparent hydrogel corneal inlay has shown to be consistently effective for the correction of presbyopia, is relatively easy to implant, and has high patient satisfaction.

Boston-According to several presentations given during the American Society of Cataracts and Refractive Surgery 2014 meeting, the investigational Raindrop (ReVision Optics) transparent hydrogel corneal inlay has shown to be consistently effective for the correction of presbyopia, is relatively easy to implant, and has high patient satisfaction.

The Raindrop is a transparent inlay, which is about 30 µm thick and 2 mm in diameter, was designed to be placed on the stroma, beneath a 150 µm femtosecond laser-created flap. The inlay is biocompatible and has a water content similar to the cornea and the same refractive index.

Reports, such as one given by Julian Theng, FROCphth, MMed, found a low complication rate and high patient satisfaction at his practice in Singapore. 

Next: Editorial: Turning pro

Shire to submit new drug application to FDA for dry eye disease

Association update: AOA advocates on Capitol Hill, AAO launches online learning center

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.